AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer.
The post FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer appeared first on MedCity News.
Recent Posts
Categories
Related Articles
How I’ve Combatted the Need to be Liked and Excessive Worry
At some point in life, many of us find ourselves stuck in...
Leave a comment